The short version of aggregation fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-16. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Masculinizing hormone therapy is typically used by transgender men, who desire the development of masculine secondary sex characteristics. Masculinizing hormone therapy usually includes testosterone to produce masculinization and suppress the production of estrogen. Treatment options include oral, subcutaneous injections or implant, and transdermal (patches, gels). Dosing is patient-specific, depending on the patient's rate of metabolism, and is discussed with the physician. The most commonly prescribed methods are intramuscular and subcutaneous injections. This dosing can be daily, weekly or biweekly depending on the route of administration and the individual patient. Unlike feminizing hormone therapy, individuals undergoing masculinizing hormone therapy do not usually require additional hormone suppression such as estrogen suppression. Therapeutic doses of testosterone are usually sufficient to inhibit the production of estrogen to desired physiologic levels. The desired effects of masculinizing hormone therapy focus on the development of masculine secondary sex characteristics. These desired effects include: increased muscle mass, increased bone turnover, development of facial hair, voice deepening, increase and thickening of body hair, and more.
== Plot == A couple and their adult son and two adult daughters live in a fenced compound. The children have no knowledge of the outside world; their parents say they will be ready to leave once they lose a dogtooth, and that one can safely leave only by car. The children entertain themselves with endurance games, such as holding their hands under hot water. They believe they have a brother on the other side of the fence to whom they throw supplies. The parents reward good behavior with stickers and bad with violence. The father pays an employee of his factory, Christina, to come to the house and have sex with the son. Frustrated by the son's refusal to give her cunnilingus, Christina trades her headband with the elder daughter in exchange for cunnilingus from her. The elder daughter convinces the younger daughter to lick her shoulder by bartering the headband. Later, the younger daughter volunteers to lick the elder again. The elder has nothing to offer in exchange, but the younger does not mind and experiments by licking other body parts. The father visits a dog training facility and demands to have his dog returned. The trainer refuses because the dog has not finished its training, and asks: "Do we want an animal or a friend?" When the children are terrified by a stray cat in the garden, the son kills it with a pair of pruning shears. Deciding to take advantage of the incident, the father shreds his clothes, covers himself in fake blood, and tells his children that their unseen brother was killed by a cat, the most dangerous creature.
Halliwell B, Watt F, Minqin R. (2023) Iron and atherosclerosis: Lessons learned from rabbits relevant to human disease. Free Radic. Biol. Med. 209, 165–170. Yau YF, Cheah IK, Mahendran R, Tang RMY, Chua RY, Goh RES, Feng L, Li J, Kua EH, Chen C, Halliwell B. (2024) Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: A pilot study. J. Alzheimer's Disease 102, 841–854.
Sources: en.wikipedia.org
=== Other nervous system side effects === Nervous-system effects include insomnia, restlessness, and rarely, seizure, convulsions, and psychosis. Other rare and serious adverse events have been observed with varying degrees of evidence for causation.
Bagwell set the record for the fewest plate appearances in a season reaching 100 of both runs scored and runs driven in and became the first National Leaguer to finish first or second in batting average, home runs, RBI, and runs scored since Willie Mays in 1955. His .750 SLG at the time ranked as the seventh-best ever and was the highest by a National Leaguer since Rogers Hornsby in 1925 (.756). Further, at the time in National League history, the 213 OPS+ trailed only Hornsby's 1924 season (222 OPS+) for the second-highest ever. The 116 RBI in 110 games qualified for the 13th-highest ratio in history. He also hit 23 home runs in 56 games at the Astrodome, setting a record that stood for the stadium that was famed to be pitcher-friendly until the Astros moved out following the 1999 season. He set single-season club records for batting average, SLG, OPS, OPS+, AB/HR, and offensive win percentage (.858), as well as home runs, breaking Wynn's 27-year-old record, and RBI, breaking Bob Watson's record 17 years earlier. Bagwell broke the team home run and RBI records later in his career. The unanimous winner of the NL Most Valuable Player Award, he became the fourth player in National League history to win by this distinction, and the first Astros player to win the award. Bagwell also won his first Silver Slugger, Gold Glove, and Player of the Year Awards from The Sporting News, Associated Press, Baseball Digest, and USA Today Baseball Weekly. "Crazy stuff happened that year", Bagwell recalled of his 1994 season. "Every pitch that I was looking for, I got.
He saw that Britain's future lay in being part of the European Economic Community, and he established ties with the European Organization for Nuclear Research (CERN), the European Molecular Biology Organization (EMBO) and the European Space Research Organization (ESRO). In 1959, the Royal Society provided for only one research fellowship, the Foulerton Professorship, but in 1961, at his suggestion, the Henry Dale Research Professorship was created for a researcher in physiology and pharmacology. Government funding was provided to create three more professorships in 1964, and another two in 1967. Reflecting his attempt to move with the times, a chair was established for the social sciences, and two new lecture series were instituted, for technology and the behavioural sciences. Aware of the acute danger of overpopulation that the life-saving drugs that he had pioneered could cause, he established a population study group, and in 1967, he became the president of the Family Planning Association.
Minh Le (Vietnamese: Lê Minh; born June 27, 1977), also known by his online nickname Gooseman, is a Vietnamese-Canadian video game programmer who co-created the Half-Life mod Counter-Strike with Jess Cliffe in 1999 and started the Counter-Strike series. He was later employed by Valve, the developers of Half-Life, and worked for 8 years in Korea on the multiplayer first-person shooter Tactical Intervention. He is a contractor on the multiplayer survival first-person shooter Rust. In the small-team games that he has worked on, Le has been a programmer, modeler, and designer. His nickname comes from Shane Gooseman, one of the main characters of 1980s cartoon series The Adventures of the Galaxy Rangers.
Sources: en.wikipedia.org
A 2016 review of the cardiovascular toxicity of nicotine concluded, "Based on current knowledge, we believe that the cardiovascular risks of nicotine from e-cigarette use in people without cardiovascular disease are quite low. We have concerns that nicotine from e-cigarettes could pose some risk for users with cardiovascular disease." A 2018 Cochrane review found that, in rare cases, nicotine replacement therapy can cause non-ischemic chest pain (i.e., chest pain that is unrelated to a heart attack) and heart palpitations, but does not increase the incidence of serious cardiac adverse events (i.e., myocardial infarction, stroke, and cardiac death) relative to controls.
== Overview == The organisation and contents of laboratories are determined by the differing requirements of the specialists working within. A physics laboratory might contain a particle accelerator or vacuum chamber, while a metallurgy laboratory could have apparatus for casting or refining metals or for testing their strength. A chemist or biologist might use a wet laboratory, while a psychologist's laboratory might be a room with one-way mirrors and hidden cameras in which to observe behavior. In some laboratories, such as those commonly used by computer scientists, computers (sometimes supercomputers) are used for either simulations or the analysis of data. Scientists in other fields will still use other types of laboratories. Engineers use laboratories as well to design, build, and test technological devices. Scientific laboratories can be found as research room and learning spaces in schools and universities, industry, government, or military facilities, and even aboard ships and spacecraft.
=== Pain management === β-Endorphin has been primarily studied for its influence on nociception (i.e., pain perception). β-endorphin modulates pain perception both in the central nervous system and the peripheral nervous system. When pain is perceived, pain receptors (nociceptors) send signals to the dorsal horn of the spinal cord and then up to the hypothalamus through the release of a neuropeptide called substance P. In the peripheral nervous system, this signal causes the recruitment of T-lymphocytes, white blood cells of the immune system, to the area where pain was perceived. T-lymphocytes release β-endorphin in this localized region, allowing it to bind to opioid receptors, causing direct inhibition of substance P. In the central nervous system, β-endorphin binds to opioid receptors in the dorsal root and inhibits the release of substance P in the spinal cord, reducing the number of excitatory pain signals sent to the brain. The hypothalamus responds to the pain signal by releasing β-endorphin through the periaqueductal grey network, which mainly acts to inhibit the release of GABA, a neurotransmitter which prevents the release of dopamine. Thus, the inhibition of GABA release by β-endorphin allows for a greater release of dopamine, in part contributing to the analgesic effect of β-endorphin. The combination of these pathways reduces pain sensation, allowing for the body to stop a pain impulse once it has been sent.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.